OakChart

Bicycle Therapeutics Plc ADR

BCYCHealthcare·Biotechnology·United Kingdom·Micro·NASD·Nov 11 • 11:41 AM ET

3.72+0.03 (0.81%)
2026-11-11 17:43 CET
Market cap
186.55 USD m
Revenue, TTM
83.44 USD m
Net income, TTM
-141.74 USD m
Free cash flow, TTM
-176.73 USD m
EPS diluted, TTM
-2.03
P/E
-
Compare

Price

BCYC against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.001.5M3.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BCYCclose 3.7220-day 3.6550-day 3.74200-day 4.443.7252w low

52.5% under the 52-week high of 7.83 on 28 Nov 2025. 52-week low 3.33 on 2 Oct 2026. Last 15 sessions, 21.1% high to low

Profile

BCYC
52-week range, 9% of the way up
3.337.83

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Employees288
IPOMay 23, 2019
Beta1.60
ATR, 14d0.20
Rel volume0.39
Short float8.47%
Insider own9.89%
Inst own63.75%

Snapshot

6 groups

Valuation

Index-
Market Cap188.08M
Enterprise Value-267.18M
Income-141.74M
Sales83.44M
Book/sh7.22
Cash/sh9.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees288
IPOMay 23, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S2.25
P/B0.52
P/C0.40
P/FCF-
EV/EBITDA-
EV/Sales-3.20
Quick Ratio12.09
Current Ratio12.09
Debt/Eq0.03
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.03
EPS next Y-2.33
EPS next Q-0.43
EPS this Y31.68%
EPS next Y-8.01%
EPS next 5Y7.58%
EPS past 3/5Y5.87% -3.36%
Sales past 3/5Y71.38% 47.36%
EPS Y/Y TTM43.93%
Sales Y/Y TTM194.79%
EPS Q/Q82.33%
Sales Q/Q191.92%
EarningsOct 29 BMO
EPS/Sales Surpr.62.41% 178.83%

Ownership

Insider Own9.89%
Insider Trans-0.64%
Inst Own63.75%
Inst Trans-1.74%
ROA-21.30%
ROE-25.23%
ROIC-27.33%
Gross Margin94.48%
Oper. Margin-218.20%
Profit Margin-169.87%
SMA201.88%
SMA50-0.43%
SMA200-16.15%
Trades-

Technical

Shs Outstand50.56M
Shs Float45.56M
Short Float8.47%
Short Ratio9.21
Short Interest3.86M
52W High7.83 -52.49%
52W Low3.33 11.71%
Volatility5.46% 5.75%
ATR (14)0.20
RSI (14)51.06
Beta1.60
Rel Volume0.39
Avg Volume418.76K
Volume60,021

Performance

Perf Week0.00%
Perf Month2.48%
Perf Quarter-6.53%
Perf Half Y-21.52%
Perf YTD-47.46%
Perf Year-45.53%
Perf 3Y-72.01%
Perf 5Y-93.58%
Perf 10Y-
Recom1.60
Target Price9.86
Prev Close3.69
Price3.72
Change %0.81%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 24, 2025InitiatedTTruistHold$19+410.8%
Oct 31, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$11+195.7%
Nov 08, 2024InitiatedSStephensEqual-Weight$25+572.0%
Sep 06, 2024InitiatedRRBC Capital MktsOutperform$35+840.9%
Aug 07, 2024DowngradeRB. Riley SecuritiesBuy → Neutral$33 → $28+652.7%
Sep 11, 2023UpgradeRB. Riley SecuritiesNeutral → Buy
Aug 31, 2022InitiatedCCowenOutperform
Jul 28, 2022InitiatedBBarclaysOverweight$30+706.5%
Jul 06, 2022ResumedCCanaccord GenuityBuy$60+1,512.9%
Apr 13, 2022DowngradeRB. Riley SecuritiesBuy → Neutral$62 → $33+787.1%

Peers

Mkt cap
TickerCompanyMkt cap
STROSutro Biopharma Inc167.80M
CTMXCytomX Therapeutics Inc461.08M
PYXSPyxis Oncology Inc199.15M
IPHAInnate Pharma ADR170.90M
PFEPfizer Inc166.03B
TLXTelix Pharmaceuticals Ltd ADR3.30B
ADCTAdc Therapeutics SA199.16M
CATXPerspective Therapeutics Inc96.80M
CGENCompugen Ltd198.45M
ZYMEZymeworks BC Inc2.08B

Insider trading

latest 14 of 59
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Swanton Robert CharlesDirectorOct 02 '26Sale3.473,43111,90615,782Oct 06 04:45 PM
Skynner MichaelCHIEF SCIENTIFIC OFFICEROct 02 '26Sale3.471,9426,739155,229Oct 06 04:45 PM
Skynner MichaelCHIEF SCIENTIFIC OFFICEROct 05 '26Sale3.575031,796154,726Oct 06 04:45 PM
Hannay Michael Charles FergusoCHIEF PROD & SUPPLY CHAIN OFFOct 02 '26Sale3.471,5725,45592,803Oct 06 04:45 PM
Hannay Michael Charles FergusoCHIEF PROD & SUPPLY CHAIN OFFOct 05 '26Sale3.5724286492,561Oct 06 04:45 PM
Perry Jennifer ScottChief Operating OfficerOct 02 '26Sale3.471,0943,79689,958Oct 06 04:45 PM
Perry Jennifer ScottChief Operating OfficerOct 05 '26Sale3.744061,51789,552Oct 06 04:45 PM
Lee KevinCHIEF EXECUTIVE OFFICEROct 02 '26Sale3.476,16721,399597,504Oct 06 04:45 PM
Lee KevinCHIEF EXECUTIVE OFFICEROct 05 '26Sale3.571,6385,848595,866Oct 06 04:45 PM
Thompson Travis AlvinChief Financial OfficerOct 02 '26Sale3.478933,09964,528Oct 06 04:34 PM
Thompson Travis AlvinChief Financial OfficerOct 05 '26Sale3.577928264,449Oct 06 04:34 PM
Lee KevinOfficerOct 02 '26Proposed Sale3.479,00031,231Oct 02 04:07 PM
Perry Jennifer ScottChief Operating OfficerJul 02 '26Sale4.271,0364,42491,428Jul 07 05:00 PM
Perry Jennifer ScottChief Operating OfficerJul 06 '26Sale4.343761,63191,052Jul 07 05:00 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
BBCVirtus Biotech Clinical Trials ETFAUM: 31.57M
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
APIEActivePassive International Equity ETFAUM: 1.13B
MEDXHorizon Kinetics Medical ETFAUM: 17.88M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M
PEPTREX Peptide ETFAUM: 3.32M

News

latest 14 of 206
  • Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results (Business Wire)
  • Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results (Business Wire)
  • Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting (Business Wire)
  • Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (Business Wire)
  • Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting (Business Wire) -6.81%
  • Loading…
  • Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 (Business Wire)
  • Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026 (Business Wire) -7.30%
  • Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
  • Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline (Business Wire) -7.55%
  • Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 (Business Wire)
  • Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline (Business Wire)
  • Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
  • Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results (Business Wire) +7.09%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.150-0.399-0.15034.0712.2210
2026Q22026-07-30-0.720-0.576-0.7220.624.229
2026Q12026-04-30-0.870-0.621-0.8710.917.5011
2025Q42026-03-17-0.290-0.937-0.29047.987.0413
2025Q32025-10-30-0.850-1.078-0.84711.728.0013
2025Q22025-08-08-1.140-0.946-1.1542.919.4313
2025Q12025-05-01-0.880-0.842-0.8819.988.2412
2024Q42025-02-25-0.750-0.857-0.7443.715.4215
2024Q32024-10-31-0.740-0.797-0.7442.686.8214
2024Q22024-08-06-0.770-1.108-0.7679.366.1313
2024Q12024-05-02-0.620-1.251-0.62419.536.0612
2023Q42024-02-20-1.160-1.233-1.1685.336.9813
2023Q32023-11-02-1.260-1.201-1.2545.3512.9415
2023Q22023-08-03-1.410-1.200-1.00811.405.7814
2023Q12023-05-04-1.300-1.078-0.9304.903.8814
2022Q42023-02-28-1.010-1.059-1.0173.193.5515

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.770-2.696-2.78313.809.99
2020FY-2.660-2.275-2.68510.399.30
2021FY-2.670-2.690-2.66611.7013.41
2022FY-3.800-3.842-3.79814.4614.87
2023FY-5.080-5.224-5.09626.9830.09
2024FY-2.900-3.019-2.90535.2837.29
2025FY-3.160-3.855-3.16072.5932.40
2026FY--2.159--37.57
2027FY--2.332--9.06
2028FY--2.494--17.05
2029FY--2.299--26.54
2030FY--1.433--130.24

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-109142.360.2014.40
2026Q4S2026-11-078132.530.2014.40
2026Q4S2026-11-029132.470.2014.40
2026Q4S2026-10-299142.470.2014.40
2026Q4S2026-10-139011.660.206.00
2026Q4S2026-08-199061.660.206.00
2026Q4S2026-07-309052.420.207.50
2026Q4S2026-07-208015.360.7019.11
2026Q4S2026-07-149015.790.7019.11
2026Q4S2026-06-099335.790.7019.11
2026Q4S2026-06-0210345.260.5019.11
2026Q4S2026-06-0110345.260.5019.11
2026Q4S2026-04-3010345.260.5019.10
2026Q4S2026-04-0710116.622.9710.00

Estimate history

EPS, annual-0.918-1.218-2.783-2.685-2.666-3.798-5.096-2.905-3.168-2.0336
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.744-0.744-0.881-1.154-0.847-0.29-0.871-0.722-0.15
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.0827.12413.85810.47111.69614.45427.08135.2972.75683.44
Period201720182019202020212022202320242025TTM
Sales, quarterly2.7033.67410.0152.95611.66147.8860.8860.6334.04
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.90117.90117.99421.09529.57929.87437.72647.56949.9350.555
Period201720182019202020212022202320242025MRQ
Shares, quarterly47.52447.56947.7149.81649.86949.9350.26950.37650.555
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue83.4472.7635.2927.0814.4511.7010.4713.867.12
Cost of Goods Sold Incl. D&A4.606.447.186.573.69----
Gross Profit78.8466.3228.1120.5110.77----
Selling, General and Administrative Excl. Other260.91349.62280.58236.15149.0978.5462.8339.0028.42
Research and Development199.00275.85216.26182.66103.8647.8734.1125.6520.73
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-182.07-283.30-252.47-215.64-138.33-68.25-53.65-26.11-22.01
Interest Expense0.190.211.733.283.342.980.460.000.00
Unusual Expense0.000.00-3.520.000.000.000.005.400.66
Net Income Before Taxes-162.89-254.32-217.09-204.46-134.97-68.47-52.14-30.99-22.20
Income Taxes-21.15-34.85-47.99-23.09-22.32-1.66-0.73-0.26-0.40
Consolidated Net Income-141.74-219.47-169.10-181.36-112.65-66.81-51.41-30.73-21.81
Net Income From Continuing Operations-141.74-219.47-169.10-181.36-112.65-66.81-51.41-30.73-21.81
Net Income-141.74-219.47-169.10-181.36-112.65-66.81-51.41-30.73-21.81
EPS (Recurring)-2.03-3.17-2.95-5.10-3.80-2.67-2.68-2.44-1.19
EPS (Basic, Before Extraordinaries)-2.03-3.17-2.91-5.10-3.80-2.67-2.69-2.78-1.22
EPS (Diluted)-2.03-3.17-2.91-5.10-3.80-2.67-2.69-2.78-1.22
EBITDA-177.47-276.86-245.29-209.07-134.64-66.84-52.36-25.14-21.30
Non-Operating Income (Expense)19.3729.1833.5814.466.702.761.970.520.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense24.0031.2530.1025.7621.149.795.322.510.83
Price To Sales Ratio3.096.7423.0923.7660.74130.4332.827.52-
Gross Margin94.4891.1579.6675.7374.49----
Operating Margin-218.20-389.38-715.41-796.30-957.00-583.57-512.37-188.38-308.94
Net Margin-169.87-301.66-479.18-669.72-779.35-571.25-490.95-221.78-306.14
Shares Outstanding50.5649.9347.5737.7329.8729.5821.0917.9917.90
Market Capitalization186.55186.55966.22766.32878.481,789.56375.80168.80174.53

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue34.040.630.8947.8911.662.9610.023.67
Cost of Goods Sold Incl. D&A1.071.071.131.331.751.721.641.69
Gross Profit32.97-0.44-0.2446.559.921.248.381.99
Selling, General and Administrative Excl. Other51.2860.7471.2677.6382.78101.3487.9980.35
Research and Development38.2447.7654.8458.1565.6383.5868.6361.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.31-61.18-71.50-31.08-72.87-100.10-79.62-78.37
Interest Expense0.040.040.050.060.040.050.050.05
Unusual Expense0.000.000.000.000.000.000.00-4.43
Net Income Before Taxes-14.14-56.86-66.58-25.32-66.10-91.84-71.42-64.34
Income Taxes-3.67-6.43-5.85-5.19-7.37-11.91-10.43-12.97
Consolidated Net Income-10.47-50.42-60.72-20.12-58.73-79.93-60.99-51.37
Net Income From Continuing Operations-10.47-50.42-60.72-20.12-58.73-79.93-60.99-51.37
Net Income-10.47-50.42-60.72-20.12-58.73-79.93-60.99-51.37
EPS (Recurring)-0.15-0.72-0.87-0.29-0.85-1.15-0.88-0.79
EPS (Basic, Before Extraordinaries)-0.15-0.72-0.87-0.29-0.85-1.15-0.88-0.74
EPS (Diluted)-0.15-0.72-0.87-0.29-0.85-1.15-0.88-0.74
EBITDA-17.24-60.11-70.38-29.74-71.12-98.38-77.98-76.68
Non-Operating Income (Expense)4.214.374.985.826.828.328.259.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.285.075.479.196.897.557.628.09
Price To Sales Ratio3.094.855.106.7718.9524.8822.8027.41
Gross Margin96.85-69.63-27.2897.2185.0341.9283.6254.05
Operating Margin-53.78-9,709.39-8,074.86-64.90-624.90-3,386.23-794.95-2,133.28
Net Margin-30.77-8,002.07-6,857.39-42.03-503.66-2,703.84-608.94-1,398.44
Shares Outstanding50.5650.3850.2749.9349.8749.8247.7147.57
Market Capitalization186.55213.14231.68353.07385.98480.96586.33966.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments628.66879.52526.42339.15438.68135.9992.1263.3867.66
Short Term Receivables35.5935.6524.0421.2111.9114.637.1411.313.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets18.6313.4311.419.027.975.104.882.080.85
Total Current Assets682.88928.61561.87369.38458.56155.72104.1576.7771.51
Net Property, Plant & Equipment21.9117.1927.6832.7717.793.614.351.821.36
Total Investments and Advances0.060.550.550.000.000.000.000.000.00
Other Assets12.7510.535.258.463.451.821.703.041.13
Total Assets717.60956.87595.34410.61479.79161.15110.1981.6374.00
Short Term Debt Incl. Current Port. of LT Debt2.765.504.883.122.380.840.640.000.00
Accounts Payable9.6715.7913.056.472.721.361.951.892.06
Income Tax Payable------0.000.010.09
Other Current Liabilities44.5645.9351.6143.7431.1320.926.237.037.29
Total Current Liabilities56.9867.2369.5453.3436.2423.138.828.939.45
Long Term Debt14.773.9940.0841.2041.9514.931.250.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities35.8792.59114.8045.2855.3527.636.9220.3315.29
Total Liabilities107.62163.81224.41139.83133.5465.6917.0029.2524.74
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00122.2096.44
Common Equity609.98793.06370.93270.78346.2595.4693.20-69.83-47.18
Total Shareholders Equity609.98793.06370.93270.78346.2595.4693.2052.3749.26
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity609.98793.06370.93270.78346.2595.4693.2052.3749.26
Total Liabilities & Stockholders Equity717.60956.87595.34410.61479.79161.15110.1981.6374.00
Book Value Per Share8.7911.488.749.0611.714.535.18-3.90-2.64
Tangible Book Value Per Share12.2216.679.839.0611.714.535.18-3.90-2.64
Full-Time Employees288305284236119877260-
Price to Book Ratio0.511.161.843.035.203.971.821.83-
Return on Assets-26.21-21.79-36.06-25.30-20.85-37.89-32.05-28.04-38.29
Return on Equity-31.29-29.06-56.52-36.51-30.25-54.50-42.23-45.69-57.38
Return on Invested Capital-35.13-21.22-44.13-36.11-17.21-46.57-32.54-41.64-33.36
Quick Ratio11.9813.818.086.9212.656.7311.818.607.57
Current Ratio11.9813.818.086.9212.656.7311.818.607.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-141.54-219.47-169.10-181.36-112.65-66.81-51.41-30.73-21.81
Depreciation4.606.447.186.573.691.411.290.960.71
Other Funds (Non Cash)30.3939.5635.8233.6527.2012.556.648.501.69
Funds from Operations-104.91-174.33-131.33-137.82-86.73-52.85-43.48-21.27-19.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-69.97-75.93-33.4676.960.6738.0625.55-7.46-6.62
Cash from Operating Activities-174.88-250.26-164.79-60.86-86.06-14.79-17.93-28.73-26.03
Capital Expenditures-1.86-2.36-1.24-2.94-18.98-2.03-1.21-1.56-1.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.86-2.36-1.24-2.94-18.98-2.03-1.21-1.56-1.18
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.050.04551.89251.006.69305.6948.7958.6825.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.050.04551.89251.006.69305.6948.7958.6825.39
Proceedsfrom Stock Options0.000.000.000.000.00305.6948.7958.6825.39
Issuance or Reduction of Debt, Net0.000.00-31.920.000.0015.0014.540.000.00
Change in Long Term Debt0.000.00-31.920.000.0015.0014.540.000.00
Issuance of Long Term Debt0.000.000.000.000.0015.0014.540.000.00
Reduction of Long Term Debt0.000.00-31.920.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.15-0.13519.97251.006.69320.6963.3358.6825.39
Exchange Rate Effect-1.700.81-0.691.35-1.12-1.210.020.47-2.44
Net Change in Cash-178.59-251.94353.25188.54-99.46302.6544.2128.86-4.28
Free Cash Flow-176.73-252.61-166.03-63.80-105.03-16.82-19.14-30.29-27.22
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit--0.85-5.233.32-4.970.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments469.93510.05560.02628.66648.33721.45
Short Term Receivables52.3647.4240.9235.5967.2660.75
Inventories0.000.000.000.000.000.00
Other Current Assets15.2717.7718.2018.6323.2322.06
Total Current Assets537.56575.24619.13682.88738.82804.26
Net Property, Plant & Equipment17.6518.6720.2721.9111.4214.11
Total Investments and Advances0.060.060.060.060.550.55
Other Assets11.9212.6112.9312.7513.1613.26
Total Assets567.18606.58652.40717.60763.95832.18
Short Term Debt Incl. Current Port. of LT Debt1.320.981.462.764.765.43
Accounts Payable9.595.665.979.6712.6518.26
Other Current Liabilities33.5540.9941.4644.5651.8753.73
Total Current Liabilities44.4647.6348.8956.9869.2877.42
Long Term Debt13.3514.2314.4814.771.722.55
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities4.1034.4634.7135.8774.4783.29
Total Liabilities61.9096.3298.08107.62145.47163.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity505.28510.25554.32609.98618.48668.91
Total Shareholders Equity505.28510.25554.32609.98618.48668.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity505.28510.25554.32609.98618.48668.91
Total Liabilities & Stockholders Equity567.18606.58652.40717.60763.95832.18
Book Value Per Share7.227.317.958.798.929.66
Tangible Book Value Per Share9.9910.1311.0312.2212.4013.43
Full-Time Employees---288--
Price to Book Ratio0.510.530.530.790.800.65
Return on Assets-21.30-26.41-28.58-26.25-28.51-25.79
Return on Equity-25.23-32.23-33.91-31.33-34.64-31.58
Return on Invested Capital-2.02-9.61-10.68-3.22-9.47-11.90
Quick Ratio12.0912.0812.6611.9810.6610.39
Current Ratio12.0912.0812.6611.9810.6610.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-10.46-50.41-60.72-19.95-58.62-79.92
Depreciation1.071.071.131.331.751.72
Other Funds (Non Cash)5.416.416.9211.658.719.56
Funds from Operations-3.26-42.61-52.92-6.12-48.20-68.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-37.01-7.09-12.90-12.98-22.43-4.84
Cash from Operating Activities-40.27-49.69-65.81-19.10-70.63-73.82
Capital Expenditures-0.30-0.27-0.71-0.57-0.67-0.51
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.30-0.27-0.71-0.57-0.67-0.51
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.010.030.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.010.030.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.03-0.05-0.05-0.01-0.03-0.05
Exchange Rate Effect0.51-0.05-1.94-0.22-1.261.82
Net Change in Cash-40.09-50.06-68.52-19.91-72.60-72.55
Free Cash Flow-40.57-49.96-66.53-19.67-71.31-74.33

Revenue breakdown

Pharmaceutical Preparations2024: 35.28M 2025: 72.59M
United Kingdom2024: 35.28M 2025: 72.59M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.47%3.9M45.6M413.44K
2026-10-157.61%3.5M45.4M385.12K
2026-09-307.28%3.3M45.4M355.29K
2026-09-157.34%3.3M45.4M392.39K
2026-08-317.23%3.3M45.4M421.03K
2026-08-147.11%3.2M45.4M429.66K
2026-07-316.81%3.0M43.8M436.08K
2026-07-156.82%3.0M43.7M450.46K
2026-06-306.60%2.9M43.7M456.81K
2026-06-156.47%2.8M43.7M481.34K
2026-05-296.55%2.9M43.7M429.10K
2026-05-156.18%2.7M43.7M445.37K
2026-04-306.71%2.9M43.6M476.17K
2026-04-156.24%2.6M42.2M454.94K
2026-03-315.35%2.3M42.9M425.67K
2026-03-135.11%2.2M42.9M331.65K
2026-02-274.94%2.1M42.9M316.40K
2026-02-134.98%2.1M42.9M310.37K
2026-01-304.48%2.0M44.4M295.56K
2026-01-154.40%2.0M44.4M299.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.205.000.000.0000.000.000.972-0.0120.000
call2.000.004.900.000.0000.000.000.903-0.0230.001
call3.000.004.901.940.0001.000.000.806-0.0180.002
call4.000.050.900.134.3761,1290.000.590-0.0540.002
call5.000.004.900.155.62812.000.000.548-0.0730.002
call6.000.000.500.204.4472.000.000.382-0.0520.002
call7.000.000.300.004.0950.000.000.269-0.0420.002
put1.000.004.900.007.7580.000.00-0.045-0.0240.001
put2.000.004.900.004.0950.000.00-0.097-0.0230.001
put3.000.000.050.061.99630.000.00-0.197-0.0180.002
put4.000.001.000.383.5751670.00-0.402-0.0550.002
put5.000.004.900.0029.0090.000.00-0.451-0.0730.002
put6.000.105.000.0015.8370.000.00-0.619-0.0560.002
put7.001.005.800.0014.9190.000.00-0.732-0.0440.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-074/A2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-063/A2023-06-22SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-208-KCurrent report2026-08-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-04SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100062.70K11
2026-090000
2026-080000
2026-070060.46K10
2026-060000
2026-050000
2026-040069.98K10
2026-030000
2026-020000
2026-0100328.26K12
2025-120000
2025-110000

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP21.65%
FCPM III SERVICES B.V.6.90%
ARMISTICE CAPITAL, LLC6.76%
Long Focus Capital Management, LLC6.59%
ACADIAN ASSET MANAGEMENT LLC3.96%
RENAISSANCE TECHNOLOGIES LLC3.05%
GSK plc3.04%
PRICE T ROWE ASSOCIATES INC /MD/1.79%
MARSHALL WACE, LLP1.59%
Qube Research & Technologies Ltd1.54%

Funds

Fund% owned
T. Rowe Price Health Sciences Fund, Inc.1.25%
SmallCap Fund1.03%
Old Westbury Small & Mid Cap Strategies Fund0.53%
iShares Biotechnology ETF0.48%
Virtus Biotech Clinical Trials Etf0.15%
T. Rowe Price Health Sciences Portfolio0.13%
ALPS Medical Breakthroughs ETF0.12%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF0.06%
VOYA MULTI-MANAGER INTERNATIONAL SMALL CAP FUND0.06%
Fidelity Nasdaq Composite Index Fund0.05%

OakChart. BCYC. Cached 15 minutes.